Literature DB >> 1800644

Cyclosporin in the management of polymyositis and dermatomyositis.

C J Lueck1, P Trend, M Swash.   

Abstract

Three patients with polymyositis refractory to conventional steroid and immunosuppressive treatment, but responsive to cyclosporin A, are described. In a fourth patient cyclosporin A was used as a first line drug in combination with steroids in the treatment of life-threatening dermatomyositis. Cyclosporin A in the management of polymyositis/dermatomyositis requires formal assessment of its costs and benefits compared with conventional treatments.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1800644      PMCID： PMC1014627          DOI： 10.1136/jnnp.54.11.1007

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  6 in total

1.  Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy.

Authors:  S Carpenter; G Karpati; I Heller; A Eisen
Journal:  Neurology       Date:  1978-01       Impact factor: 9.910

2.  Severe dermatomyositis treated with cyclosporin A.

Authors:  L Ejstrup
Journal:  Ann Rheum Dis       Date:  1986-07       Impact factor: 19.103

3.  Cell-mediated cytotoxicity to muscle in polymyositis. Effect of immunosuppression.

Authors:  R L Dawkins; F L Mastaglia
Journal:  N Engl J Med       Date:  1973-03-01       Impact factor: 91.245

4.  Cyclosporin for acute dermatomyositis.

Authors:  P Zabel; G Leimenstoll; W L Gross
Journal:  Lancet       Date:  1984-02-11       Impact factor: 79.321

5.  Cyclosporin for polymyositis.

Authors:  K Bendtzen; N Tvede; V Andersen; G Bendixen
Journal:  Lancet       Date:  1984-04-07       Impact factor: 79.321

6.  Management of polymyositis and dermatomyositis.

Authors:  B M Ansell
Journal:  Clin Rheum Dis       Date:  1984-04
  6 in total
  8 in total

Review 1.  Progressive multifocal leukoencephalopathy during cyclosporine treatment. A case report.

Authors:  S Gentile; I Sacerdote; D Roccatello; M T Giordana
Journal:  Ital J Neurol Sci       Date:  1996-10

Review 2.  Treatment of inflammatory myopathies.

Authors:  A C Cordeiro; D A Isenberg
Journal:  Postgrad Med J       Date:  2006-07       Impact factor: 2.401

Review 3.  Recognition and management of myositis.

Authors:  P Cherin
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 4.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

5.  Very low-dose cyclosporin treatment of steroid-resistant interstitial pneumonitis associated with Sjögren's syndrome.

Authors:  H Ogasawara; M Sekiya; A Murashima; T Hishikawa; Y Tokano; I Sekigawa; N Iida; H Hashimoto; S Hirose
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

Review 6.  Promising and Upcoming Treatments in Myositis.

Authors:  Lauren N Smith; Julie J Paik
Journal:  Curr Rheumatol Rep       Date:  2020-08-26       Impact factor: 4.592

7.  Inflammatory Myopathy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-07       Impact factor: 3.972

Review 8.  Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies.

Authors:  Boel De Paepe; Jana Zschüntzsch
Journal:  Int J Mol Sci       Date:  2015-08-11       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.